Depomed (NASDAQ: DEPO) reported Q2 EPS of $0.27, $0.02 better than the analyst estimate of $0.25. Revenue for the quarter came in at $116.7 million versus the consensus estimate of $118.2 million.

For earnings history and earnings-related data on Depomed (DEPO) click here.